Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68


Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.

Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB.

Clin Cancer Res. 2011 Sep 15;17(18):5913-25. doi: 10.1158/1078-0432.CCR-11-0728. Epub 2011 Aug 1.


Abiraterone and increased survival in metastatic prostate cancer.

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators.

N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.


Statins and prostate cancer diagnosis and grade in a veterans population.

Farwell WR, D'Avolio LW, Scranton RE, Lawler EV, Gaziano JM.

J Natl Cancer Inst. 2011 Jun 8;103(11):885-92. doi: 10.1093/jnci/djr108. Epub 2011 Apr 15.


Modifiable risk factors for prostate cancer mortality in London: forty years of follow-up in the Whitehall study.

Batty GD, Kivimäki M, Clarke R, Davey Smith G, Shipley MJ.

Cancer Causes Control. 2011 Feb;22(2):311-8. doi: 10.1007/s10552-010-9691-6. Epub 2010 Nov 30.


The association between statin use and the diagnosis of prostate cancer in a population based cohort.

Breau RH, Karnes RJ, Jacobson DJ, McGree ME, Jacobsen SJ, Nehra A, Lieber MM, St Sauver JL.

J Urol. 2010 Aug;184(2):494-9. doi: 10.1016/j.juro.2010.03.149. Epub 2010 Jun 17.


Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database.

Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ.

Cancer. 2010 Jul 15;116(14):3389-98. doi: 10.1002/cncr.25308.


Statin use and risk of prostate cancer recurrence in men treated with radiation therapy.

Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL.

J Clin Oncol. 2010 Jun 1;28(16):2653-9. doi: 10.1200/JCO.2009.27.3003. Epub 2010 Apr 26.


Lipid rafts as a membrane-organizing principle.

Lingwood D, Simons K.

Science. 2010 Jan 1;327(5961):46-50. doi: 10.1126/science.1174621. Review.


Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.

Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Thompson IM Jr, Kristal AR.

Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2807-13. doi: 10.1158/1055-9965.EPI-09-0472. Epub 2009 Nov 3.


Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort.

Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA.

Cancer Causes Control. 2010 Jan;21(1):61-8. doi: 10.1007/s10552-009-9434-8. Epub 2009 Oct 6.


Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts.

Iso H, Ikeda A, Inoue M, Sato S, Tsugane S; JPHC Study Group.

Int J Cancer. 2009 Dec 1;125(11):2679-86. doi: 10.1002/ijc.24668.


Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS.

J Clin Oncol. 2009 Aug 10;27(23):3742-8. doi: 10.1200/JCO.2008.20.0642. Epub 2009 May 26.


Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

Harris WP, Mostaghel EA, Nelson PS, Montgomery B.

Nat Clin Pract Urol. 2009 Feb;6(2):76-85. doi: 10.1038/ncpuro1296. Review. Erratum in: Nat Clin Pract Urol. 2009 Mar;6(3):173.


Ezetimibe is an inhibitor of tumor angiogenesis.

Solomon KR, Pelton K, Boucher K, Joo J, Tully C, Zurakowski D, Schaffner CP, Kim J, Freeman MR.

Am J Pathol. 2009 Mar;174(3):1017-26. doi: 10.2353/ajpath.2009.080551. Epub 2009 Jan 29.


Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?

Singer EA, Golijanin DJ, Messing EM.

Can J Urol. 2008 Dec;15(6):4381-7.


CYP17 inhibition as a hormonal strategy for prostate cancer.

Reid AH, Attard G, Barrie E, de Bono JS.

Nat Clin Pract Urol. 2008 Nov;5(11):610-20. doi: 10.1038/ncpuro1237. Review.


Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol.

Dillard PR, Lin MF, Khan SA.

Mol Cell Endocrinol. 2008 Nov 25;295(1-2):115-20. doi: 10.1016/j.mce.2008.08.013. Epub 2008 Aug 20.


Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.

Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC.

Cancer Res. 2008 Aug 1;68(15):6407-15. doi: 10.1158/0008-5472.CAN-07-5997.


Association between plasma cholesterol and prostate cancer in the PSA era.

Platz EA, Clinton SK, Giovannucci E.

Int J Cancer. 2008 Oct 1;123(7):1693-8. doi: 10.1002/ijc.23715.


Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS.

Cancer Res. 2008 Jun 1;68(11):4447-54. doi: 10.1158/0008-5472.CAN-08-0249.

Supplemental Content

Support Center